Tag: anakinra market outlook

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Anakinra Market From 2025 To 2034?

The anakinra market size has seen rapid expansion in recent years. It is projected to increase from $4.89 billion in 2024 to $5.46 billion in 2025, achieving a compound annual growth rate (CAGR) of 11.8%. The growth observed in the historical period can be attributed to the rising prevalence of rheumatoid arthritis, the approval of anakinra for treating rare autoinflammatory conditions like NOMID, increased awareness of biologics for managing chronic inflammatory conditions, and the growing adoption of targeted therapies.

The anakinra market is anticipated to experience significant expansion in the coming years. It is projected to reach $8.6 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.0%. This growth in the forecast period is primarily driven by the broadened applications of anakinra for various conditions, an increasing emphasis on personalized medicine, the rising occurrence of rare autoinflammatory disorders, advancements in drug delivery systems, and expanding healthcare access in emerging markets, which in turn boosts the demand for biologics. Key trends anticipated include the evolution of biosimilars and next-generation IL-1 inhibitors, the adoption of home-based and self-administered treatment solutions, strategic collaborations between biotech companies and academic institutions, and the integration of digital health solutions to enhance patient adherence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp

Which Industry Drivers Are Expected To Accelerate The Anakinra Market From 2025 To 2029?

The growing prevalence of autoimmune disorders is projected to fuel the expansion of the anakinra market in the future. These disorders involve the body’s immune system mistakenly attacking and destroying its own healthy tissues and organs, perceiving them as threats. The increasing occurrence of autoimmune disorders stems from genetic susceptibility and environmental elements, including infections, pollution, and shifts in diet, which collectively contribute to their heightened frequency. Anakinra serves as a treatment for autoimmune disorders by inhibiting interleukin-1 (IL-1) activity, thereby alleviating inflammation in conditions such as rheumatoid arthritis, Still’s disease, and periodic fever syndromes. As an illustration, a report released in June 2024 by the Australian Institute of Health and Welfare, an Australian government body, indicated that during 2021–22, hospitalizations for rheumatoid arthritis reached 10,000, marking a 25% rise from 8,000 in the preceding year, which corresponds to a rate of 39 hospitalizations per 100,000 population. Consequently, the increasing prevalence of autoimmune disorders is propelling the expansion of the anakinra market.

What Are The Leading Segments Analyzed In The Anakinra Market?

The anakinra market covered in this report is segmented –

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies

3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares

5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis

Which Ongoing Trends Are Expected To Shape The Anakinra Market Outlook?

Major companies within the Anakinra market are securing regulatory approvals to broaden the approved uses for new therapeutic applications. These regulatory approvals signify formal authorizations from government agencies, enabling a drug to be marketed and prescribed for specific medical conditions after an evaluation of its safety, efficacy, and quality. For instance, in November 2022, the Food and Drug Administration, a US government agency, granted Emergency Use Authorization (EUA) for Kineret (anakinra) to treat hospitalized adults with COVID-19-related pneumonia requiring supplemental oxygen, aiming to mitigate the risk of severe respiratory failure. This authorization was founded on the SAVE-MORE phase 3 study, which demonstrated that early treatment with Kineret improved patient outcomes. Kineret functions by blocking the cytokines IL-1a and IL-1ß, which contribute to the hyperinflammatory response observed in severe COVID-19 cases. While it does not hold full FDA approval for this indication, it is authorized for temporary use during the public health emergency.

Which Leading Companies Dominate The Anakinra Market Share?

Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report

What Are The Key Regional Factors Influencing The Anakinra Market Growth?

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Anakinra Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21095&type=smp

Browse Through More Reports Similar to the Global Anakinra Market 2025, By The Business Research Company

Arthritis Monoclonal Antibodie Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report

Psoriatic Arthritis Treatments Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

Companion Animal Arthritis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/companion-animal-arthritis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Anakinra Market Be Worth By 2029?

The market size for anakinra has experienced swift growth in the past few years. Projected to rise from $4.89 billion in 2024 to $5.46 billion in 2025, it is anticipated to expand at a compound annual growth rate (CAGR) of 11.8%. The expansion in the market during the historic period is largely due to several factors such as, an increase in occurrence of rheumatoid arthritis, the endorsement of anakinra in treating uncommon autoinflammatory conditions such as NOMID, a heightened awareness of biologics’ role in managing persistent inflammatory conditions, and a surge in the adoption of targeted therapies.

The market for anakinra is projected to experience significant expansion in the imminent years, with a forecasted size of “$8.6 billion in 2029” representing a compound annual growth rate (CAGR) of 12.0%. This predicted surge over the forecast period can be associated with expanded usage indications for anakinra, an intensified focus on tailored medical treatments, a growing occurrence of uncommon autoinflammatory disorders, progress in drug delivery systems, and increased health care availability in developing markets driving biologics demand. Notable trends anticipated during the forecast period involve the emergence of biosimilars and next-generation IL-1 inhibitors, the uptake of home-based and self-administered treatments, partnerships between biotech firms and educational establishments, and the application of digital health technologies to enhance patient compliance.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp

What Underlying Factors Are Supporting The Anakinra Market Growth?

The increasing number of autoimmune disorder cases is predicted to boost the anakinra market’s expansion. Autoimmune disorders are conditions where the body’s immune system wrongly attacks and damages its own healthy tissues and organs, considering them as external threats. The surge in the number of these disorders is influenced by both genetic predisposition and environmental elements, such as contaminations, pollution, and shifts in diet, all of which play a part in this upsurge. Anakinra is utilized to manage autoimmune disorders by inhibiting interleukin-1 (IL-1) activity, thus reducing inflammation in problems like rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For example, as per an Australian Institute of Health and Welfare’s report in June 2024, an organization based in Australia, the hospitalizations for rheumatoid arthritis was 10,000 in the year 2021-22, marking a 25% growth from the preceding year’s 8,000. This translates to 39 hospitalizations per 100,000 population. Consequently, the growing prevalence of autoimmune disorders acts as a driving force for the anakinra market’s advancement.

How Is The Anakinra Market Organized By Different Segments?

The anakinra market covered in this report is segmented –

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies

3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares

5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis

What Current And Upcoming Trends Are Shaping The Anakinra Market?

Significant organizations operating in the Anakinra market are achieving regulatory clearances to broaden their implications for novel therapeutic uses. Regulatory clearances denote formal permissions from government bodies that permit a drug to be marketed and prescribed for specific health conditions, following assessment of its safety, effectiveness, and quality. For example, in November 2022 the US governmental agency, Food and Drug Administration, provided Emergency Use Authorization (EUA) for Kineret (anakinra), designed to treat adult hospital patients with pneumonia related to COVID-19 and requiring additional oxygen, with the objective of mitigating the risk of acute respiratory failure. This authorization arose from the SAVE-MORE phase 3 trial, which indicated that earlier treatment with Kineret enhanced patient outcomes. Kineret functions by inhibiting cytokines IL-1a and IL-1ß, factors contributing to the hyperinflammatory reaction in severe COVID-19 instances. Although it hasn’t obtained full FDA approval for this indication, it has been authorized for temporary usage during the public health crisis.

Which Firms Are Making The Biggest Impact In The Anakinra Market?

Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report

Which Region Dominates The Anakinra Market Today?

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21095&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Anakinra Market Be Worth By 2029?

The market size for anakinra has experienced swift growth in the past few years. Projected to rise from $4.89 billion in 2024 to $5.46 billion in 2025, it is anticipated to expand at a compound annual growth rate (CAGR) of 11.8%. The expansion in the market during the historic period is largely due to several factors such as, an increase in occurrence of rheumatoid arthritis, the endorsement of anakinra in treating uncommon autoinflammatory conditions such as NOMID, a heightened awareness of biologics’ role in managing persistent inflammatory conditions, and a surge in the adoption of targeted therapies.

The market for anakinra is projected to experience significant expansion in the imminent years, with a forecasted size of “$8.6 billion in 2029” representing a compound annual growth rate (CAGR) of 12.0%. This predicted surge over the forecast period can be associated with expanded usage indications for anakinra, an intensified focus on tailored medical treatments, a growing occurrence of uncommon autoinflammatory disorders, progress in drug delivery systems, and increased health care availability in developing markets driving biologics demand. Notable trends anticipated during the forecast period involve the emergence of biosimilars and next-generation IL-1 inhibitors, the uptake of home-based and self-administered treatments, partnerships between biotech firms and educational establishments, and the application of digital health technologies to enhance patient compliance.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp

What Underlying Factors Are Supporting The Anakinra Market Growth?

The increasing number of autoimmune disorder cases is predicted to boost the anakinra market’s expansion. Autoimmune disorders are conditions where the body’s immune system wrongly attacks and damages its own healthy tissues and organs, considering them as external threats. The surge in the number of these disorders is influenced by both genetic predisposition and environmental elements, such as contaminations, pollution, and shifts in diet, all of which play a part in this upsurge. Anakinra is utilized to manage autoimmune disorders by inhibiting interleukin-1 (IL-1) activity, thus reducing inflammation in problems like rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For example, as per an Australian Institute of Health and Welfare’s report in June 2024, an organization based in Australia, the hospitalizations for rheumatoid arthritis was 10,000 in the year 2021-22, marking a 25% growth from the preceding year’s 8,000. This translates to 39 hospitalizations per 100,000 population. Consequently, the growing prevalence of autoimmune disorders acts as a driving force for the anakinra market’s advancement.

How Is The Anakinra Market Organized By Different Segments?

The anakinra market covered in this report is segmented –

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies

3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares

5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis

What Current And Upcoming Trends Are Shaping The Anakinra Market?

Significant organizations operating in the Anakinra market are achieving regulatory clearances to broaden their implications for novel therapeutic uses. Regulatory clearances denote formal permissions from government bodies that permit a drug to be marketed and prescribed for specific health conditions, following assessment of its safety, effectiveness, and quality. For example, in November 2022 the US governmental agency, Food and Drug Administration, provided Emergency Use Authorization (EUA) for Kineret (anakinra), designed to treat adult hospital patients with pneumonia related to COVID-19 and requiring additional oxygen, with the objective of mitigating the risk of acute respiratory failure. This authorization arose from the SAVE-MORE phase 3 trial, which indicated that earlier treatment with Kineret enhanced patient outcomes. Kineret functions by inhibiting cytokines IL-1a and IL-1ß, factors contributing to the hyperinflammatory reaction in severe COVID-19 instances. Although it hasn’t obtained full FDA approval for this indication, it has been authorized for temporary usage during the public health crisis.

Which Firms Are Making The Biggest Impact In The Anakinra Market?

Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report

Which Region Dominates The Anakinra Market Today?

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21095&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Are the Key Milestones in the Anakinra Market’s Growth Trajectory From 2025 To 2034?#_x000D_

The market for anakinra has seen a swift expansion in the last few years. Forecasts predict an increase from $4.89 billion in 2024 to $5.46 billion in 2025, displaying a compound annual growth rate (CAGR) of 11.8%. This impressive growth in the past years can be traced back to factors like the growing number of rheumatoid arthritis cases, the greenlighting of anakinra for the treatment of uncommon autoinflammatory disorders such as NOMID, an increase in awareness about biologics’ role in managing chronic inflammation, and the escalating endorsement of targeted therapies._x000D_

_x000D_

Significant expansion is forecasted for the anakinra market size in the coming years. By 2029, it is expected to have swelled to $8.6 billion, surging at a compound annual growth rate (CAGR) of 12.0%. Influences on this predicted growth during the forecast period include new applications for anakinra in various conditions, an increased focus on customized treatments, a high incidence of rare autoinflammatory conditions, innovations in drug delivery, and expanding healthcare reach in upcoming markets, leading to a higher demand for biology-based therapies. Forecasted trends for this period involve the progression of biosimilars and novel IL-1 inhibitors, the preference for treatments that can be self-administered and taken at home, partnerships between biotech firms and academic bodies, as well as the utilization of digital health tools to ensure patient compliance._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp_x000D_

_x000D_

#What are the Fundamental Drivers and Innovations Shaping the Anakinra Market?#_x000D_

The escalating prevalence of autoimmune disorders is projected to fuel the expansion of the anakinra market in the future. Autoimmune disorders are conditions where the body’s immune system wrongly attacks its own healthy tissues and organs, mistakenly identifying them as foreign threats. Genetics and environmental factors like infections, pollution, and changes in diet are the key factors driving the higher incidence of these disorders. Anakinra is employed to manage autoimmune disorders by inhibiting interleukin-1 (IL-1) activity, thereby mitigating inflammation in conditions such as rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For example, a report released in June 2024 by the Australian Institute of Health and Welfare, a government agency based in Australia, stated that there were 10,000 hospital admissions for rheumatoid arthritis in 2021–22, a 25% surge from the prior year’s 8,000, translating into 39 hospitalizations per 100,000 population. Thus, the increasing prevalence of autoimmune disorders is spurring the growth of the anakinra market._x000D_

_x000D_

#How Is the Anakinra Market Segmented?#_x000D_

The anakinra market covered in this report is segmented – _x000D_

_x000D_

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications_x000D_

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies_x000D_

3) By End-User: Hospitals, Clinics, Homecare Settings_x000D_

_x000D_

Subsegments:_x000D_

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease _x000D_

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease _x000D_

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms _x000D_

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares _x000D_

5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction _x000D_

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management _x000D_

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21095&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Anakinra Market Growth?#_x000D_

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Trends Are Shaping the Future of the Anakinra Market?#_x000D_

Leading firms in the Anakinra market are earning regulatory consents to broaden indications for novel therapeutic uses. These regulatory approvals are formal permissions from governmental authorities that give the green light for a drug to be marketed and prescribed for particular medical conditions, based on their assessment of the drug’s safety, effectiveness, and quality. For example, the US-based governmental agency, the Food and Drug Administration (FDA), in November 2022, bestowed an Emergency Use Authorization (EUA) for Kineret (anakinra) to be utilized for the treatment of adult patients admitted to the hospital with pneumonia related to COVID-19 who need additional oxygen, with the goal of mitigating the risk of severe respiratory failure. This endorsement was founded on the SAVE-MORE phase 3 study results, demonstrating that early intervention with Kineret enhanced patient outcomes. Kineret operates by inhibiting cytokines IL-1a and IL-1ß, essentially important in the hyperinflammatory response seen in severe COVID-19 cases. Despite not yet having full FDA approval for this application, it has been granted temporary permission for use during the public health crisis._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report_x000D_

_x000D_

#How Is the Anakinra Market Defined and What Are Its Core Parameters?#_x000D_

Anakinra refers to a biopharmaceutical medication that acts as a recombinant version of the human interleukin-1 receptor antagonist. It is generally used to treat moderate-to-severe rheumatoid arthritis in individuals who have not reacted well to other disease-modifying antirheumatic medications._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21095_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Anakinra Market Grown from 2024 to 2025?

In recent times, the anakinra market has experienced swift expansion. The market, which is set to increase from a value of $4.89 billion in 2024 to $5.51 billion in 2025, will have a compound annual growth rate of 12.8%. Factors contributing to this growth during the historic period include an increased occurrence of rheumatoid arthritis, the clearance of anakinra as a treatment for uncommon autoinflammatory conditions such as NOMID, heightened awareness about biologics’ role in handling chronic inflammatory conditions, and a surge in the acceptance of targeted therapies.

What Growth Rate Is Anticipated for the Anakinra Market in the Coming Years?

In the years to come, the anakinra market is predicted to experience rapid expansion, escalating to $8.81 billion in 2029 with a compound annual growth rate (CAGR) of 12.4%. The anticipated growth during this period can be ascribed to the broadened indications of anakinra for various conditions, amplified emphasis on personalized healthcare, increasing incidents of rare autoinflammatory disorders, advances in drug delivery methods, and improved healthcare access in emerging markets, thereby enhancing demand for biological products. Key trends during this period incorporate the development of biosimilars and advanced IL-1 inhibitors, the preference for home-based and self-directed treatment methodologies, cooperation between biotech firms and educational establishments, and utilization of digital health technologies to promote patient compliance.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp

Who Are the Leading Companies in the Anakinra Market?

Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.

What Are the Key Drivers of the Anakinra Market?

The escalating occurrences of autoimmune disorders are foreseen to drive anakinra market’s growth. These disorders arise when the immune system mistakenly attacks the body’s healthy tissues and organs as if they were alien threats. Factors such as inherited predispositions, environmental influencers like pollution, infections, and dietary shifts contribute to the increasing prevalence of these conditions. Anakinra aids in treating autoimmune disorders by impeding interleukin-1 (IL-1) action, thereby minimizing inflammation in conditions such as rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For example, the Australian Institute of Health and Welfare reported in June 2024 that there were 10,000 hospitalizations for rheumatoid arthritis in 2021–22, a 25% uptick from the preceding year’s 8,000 – a rate of 39 per 100,000 population. Thus, the emergence of more autoimmune disorders is fueling the anakinra market’s expansion. The Impact Of Escalating Healthcare Costs On Market Growth

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21095&type=smp

What Are the Key Market Segments in the Anakinra Industry?

The anakinra market covered in this report is segmented –

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies

3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares

5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis

What Are the Latest Trends in the Anakinra Market?

Big market players in the Anakinra industry are achieving regulatory authorizations to broaden usage for new treatment conditions. Regulatory permissions entail formal consents from governmental bodies that greenlight a pharmaceutical product for marketing and prescribing for defined health issues, following scrutinizing its safety, effectiveness, and quality. For instance, in November 2022, the Food and Drug Administration – a Government agency from the United States – issued an Emergency Use Authorization (EUA) for Kineret (anakinra) for the purpose of treating adults who are hospitalized due to COVID-19-linked pneumonia and require supplementary oxygen, with the intention of lessening the likelihood of severe respiratory collapse. The approval was grounded on the findings from the SAVE-MORE phase 3 trial, which displayed that starting Kineret treatment early can better patient results. Kineret is designed to inhibit cytokines IL-1α and IL-1β that play a part in the intense inflammatory reaction seen in grave COVID-19 circumstances. Although it does not have full FDA approval for this specific use, it is authorized for provisional use amid the public health crisis.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report

What Are the Key Regional Markets in the Anakinra Industry?

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21095

This Report Delivers Insight On:

1. How big is the anakinra market, and how is it changing globally?

2. Who are the major companies in the anakinra market, and how are they performing?

3. What are the key opportunities and risks in the anakinra market right now?

4. Which products or customer segments are growing the most in the anakinra market?

5. What factors are helping or slowing down the growth of the anakinra market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

How Has The Anakinra Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, there has been a significant surge in the market size of Anakinra. Projected growth from 2024 estimates the market to be worth $4.89 billion and expanding to $5.51 billion in 2025 with a Compound Annual Growth Rate (CAGR) of 12.8%. The historical growth trajectory can be linked to the surge in cases of rheumatoid arthritis, the endorsement of Anakinra in treating uncommon autoinflammatory diseases like NOMID, heightened awareness of biologics in the management of recurring inflammatory conditions, and the increasing preference for targeted therapies.

In the ensuing years, the market size for anakinra is projected to experience accelerated growth, with an estimated value of $8.81 billion by 2029, boasting a 12.4% compound annual growth rate (CAGR). Key factors contributing to this projected growth span the board, including the expanding indications for anakinra in various conditions, a heightened interest in personalized medicine, the increasing prevalence of uncommon autoinflammatory disorders, progress in drug delivery systems, and enhanced healthcare accessibility in emerging markets promoting the demand for biologics. Future trends forecasted include the production of biosimilars and next-generation IL-1 inhibitors, a shift towards home-based and self-administered treatments, strategic partnerships between biotech firms and academic institutions, and an increased utilization of digital health solutions to bolster patient adherence.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp

What are the Fundamental Drivers and Innovations Shaping the Anakinra Market?

The surge in cases of autoimmune disorders, where the body’s immune system mistakenly targets and destroys healthy tissues and organs, is slated to fuel the anakinra market’s expansion. Autoimmune disorders are typically caused by a combination of genetic predisposition and environmental influences, such as infections, pollution, and alterations in diet. Anakinra works to curb these disorders through interruption of interleukin-1 (IL-1) activity, thereby lessening inflammation in ailments like rheumatoid arthritis, Still’s disease, and periodic fever syndromes. As an example, the Australian Institute of Health and Welfare reported in June 2024 that in 2021-22, rheumatoid arthritis hospitalizations increased 25% from the prior year, totaling 10,000, or 39 hospitalizations per 100,000 population. Therefore, the escalating frequency of autoimmune disorders is propelling the anakinra market. Additionally, the increase in healthcare expenditure is anticipated to drive the anakinra market’s upward trend. Healthcare expenditure encompasses the total funds spent on healthcare services and products, from hospital care and physician services to medications, devices, public health initiatives and more. The rise in healthcare expenditure is influenced by factors such as a growing elderly population, advancements in medicine, prevalence of chronic diseases, higher drug costs, increased healthcare use, administrative expenses, and inflation. Funds spent on healthcare bolster the anakinra market by promoting anakinra’s development, availability, and constant administration as an effective remedy for inflammatory conditions like rheumatoid arthritis, and by aiding its integration into healthcare systems via insurance coverage and patient access schemes. In May 2023, the Office for National Statistics reported that in 2022, the UK’s healthcare expenditure swelled to nearly $352 billion (£283 billion), a 0.7% nominal increase from 2021. Consequently, the upswing in healthcare expenditure is contributing to the anakinra market’s growth.

How Is the Anakinra Market Segmented?

The anakinra market covered in this report is segmented –

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies

3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares

5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21095&type=smp

Which Regions Are Driving the Next Phase of the Anakinra Market Growth?

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Anakinra Market?

Principal businesses in the Anakinra market are securing regulatory assents to include indications for innovative therapeutic uses. Such authorizations are essentially official permissions from government bodies which, after assessing the safety, effectiveness, and quality of a drug, allow it to be marketed and suggested for certain illnesses. In November 2022, for example, the US government body, the Food and Drug Administration, issued an Emergency Use Authorization (EUA) for Kineret (anakinra) to administer treatment to adult patients hospitalized with pneumonia due to COVID-19 who required additional oxygen, with the goal of minimizing the probability of serious respiratory failure. The affirmation was on the basis of the SAVE-MORE Phase 3 study, demonstrating that preemptive treatment with Kineret enhanced patient outcomes. Kineret operates by obstructing cytokines IL-1a and IL-1ß which catalyze the extreme inflammatory response seen in critical cases of COVID-19. Even though it doesn’t have full FDA approval for this specific indication, it has been authorized for transitory use in the course of the public health crisis.

View the full report here:

https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report

How Is the Anakinra Market Defined and What Are Its Core Parameters?

Anakinra refers to a biopharmaceutical medication that acts as a recombinant version of the human interleukin-1 receptor antagonist. It is generally used to treat moderate-to-severe rheumatoid arthritis in individuals who have not reacted well to other disease-modifying antirheumatic medications.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21095

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers Contributing to the Growth and Expansion of the Anakinra Market?

The increasing occurrence of autoimmune disorders is expected to support the growth of the anakinra market. Autoimmune disorders develop when the immune system mistakenly attacks healthy tissues and organs, perceiving them as threats. Factors such as genetic predisposition and environmental triggers, including infections, pollution, and dietary shifts, contribute to their prevalence. Anakinra, an interleukin-1 (IL-1) inhibitor, is widely used to manage inflammatory conditions such as rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For instance, in June 2024, the Australian Institute of Health and Welfare, an Australian governmental body, reported that hospitalizations for rheumatoid arthritis increased to 10,000 in 2021–22, representing a 25% rise from the previous year’s 8,000 cases. This equates to 39 hospitalizations per 100,000 individuals. Therefore, the rising prevalence of autoimmune disorders is fueling the growth of the anakinra market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp

#What is the Growth Potential of the Anakinra Market, and How Will It Perform by 2034?

The anakinra market has demonstrated rapid growth. It is forecasted to expand from $4.89 billion in 2024 to $5.51 billion in 2025 at a CAGR of 12.8%. The historical growth was driven by the increasing prevalence of rheumatoid arthritis, the approval of anakinra for rare autoinflammatory conditions such as NOMID, heightened awareness of biologic treatments for chronic inflammatory conditions, and the rising adoption of targeted therapies.

The anakinra market size is projected to experience rapid growth in the upcoming years. By 2029, it is anticipated to reach $8.81 billion, with a compound annual growth rate (CAGR) of 12.4%. Growth factors include the expansion of indications for anakinra in various conditions, a growing focus on personalized medicine, a rising prevalence of rare autoinflammatory disorders, advancements in drug delivery systems, and increasing healthcare accessibility in emerging markets driving demand for biologics. Key trends expected include the development of biosimilars and next-generation IL-1 inhibitors, a shift toward home-based and self-administered treatment options, collaborations between biotech companies and academic institutions, and the integration of digital health solutions to support patient adherence.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21095

What New Market Trends Are Reshaping theAnakinra Market and Its Opportunities?

Key companies in the Anakinra market are working on securing regulatory approvals to extend its therapeutic applications. Regulatory approvals refer to official permissions granted by government agencies, allowing a drug to be marketed for specific medical conditions after assessing its safety, efficacy, and quality. For instance, in November 2022, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Kineret (anakinra) to treat hospitalized adults with COVID-19-related pneumonia who required supplemental oxygen, aiming to reduce the risk of severe respiratory failure. This authorization was based on the SAVE-MORE phase 3 study, which demonstrated that early treatment with Kineret led to better patient outcomes. Kineret functions by blocking cytokines IL-1a and IL-1ß, which play a role in the hyperinflammatory response in severe COVID-19 cases. While it is not fully FDA-approved for this indication, it is temporarily authorized for use during the public health emergency.

Who Are the Leading Market Players Fueling Growth in the Anakinra Market Trend?

Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report

How is the Global Anakinra Market Segemented?

The anakinra market covered in this report is segmented –

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies

3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares

5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21095&type=smp

Which Geographics are Influencing the Growth of the Anakinra Market?

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Anakinra Market 2025, By The Business Research Company:

Chemotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Hormone Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Gastrointestinal Bleeding Treatment Devices Size Global Market Report 2025

https://thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the anakinra market grown in recent years?

The size of the anakinra market has experienced swift growth in the past few years. The market is projected to further expand from $4.89 billion in 2024 to $5.51 billion in 2025, with a compound annual growth rate (CAGR) of 12.8%. The surge noticed in the historic period is largely due to the rising occurrence of rheumatoid arthritis, the acceptance of anakinra for the treatment of rare autoinflammatory disorders such as NOMID, the increasing knowledge of biologics as a way to manage long-term inflammatory conditions, and the growing acceptance of targeted therapies.

How is the anakinra market size expected to evolve during the forecast period?

The market size of anakinra is projected to witness swift expansion in the coming years, eventually reaching a value of $8.81 billion in 2029, with a compound annual growth rate (CAGR) of 12.4%. This growth through the forecast period can be credited to the broader application of anakinra in multiple conditions, an increasing emphasis on personalised medicine, rising instances of rare autoinflammatory disorders, progression in drug delivery systems and improving healthcare accessibility in developing markets that is fuelling demand for biologics. Key trends during the forecast period include the production of biosimilars and innovative IL-1 inhibitors, the endorsement of home-based and self-administered treatments, partnerships between biotechnology firms and academic entities, and digital health strategies to bolster patient compliance.

Get your anakinra market report here!

https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report

Which key drivers are propelling the anakinra market’s growth?

The escalating occurrence of autoimmune disorders is anticipated to drive the expansion of the anakinra market. Autoimmune disorders are health issues in which the body’s own immune system mistakenly attacks its own healthy tissues and organs, perceiving them as external threats. The increased prevalence of autoimmune disorders could be attributed to genetic predisposition and environmental factors like infections, pollution, and changes in diet, all of which contribute to the increased presence of these disorders. Anakinra serves as a treatment for autoimmune disorders by impeding the function of interleukin-1 (IL-1), reducing inflammation in conditions such as rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For example, in June 2024, the Australian Institute of Health and Welfare, a governmental organization based in Australia, made public a report stating that in 2021–22, there were 10,000 hospitalizations for rheumatoid arthritis, marking a 25% increase from the preceding year’s 8,000. This adds up to a rate of 39 hospitalizations per 100,000 population. Therefore, the escalating occurrence of autoimmune disorders is stimulating the expansion of the anakinra market. The Impact of Surging Healthcare Expenditure on Market Growth

What are the market segments in the anakinra industry?

The anakinra market covered in this report is segmented –

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies

3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares

5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp

Which leading companies are shaping the growth of the anakinra market?

Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.

What key trends are currently impacting the anakinra market’s development?

Major firms in the Anakinra market are receiving regulatory clearances to broaden the scope for new therapeutic uses. Regulatory clearances are formal permissions granted by official government bodies, enabling a drug to be marketed and prescribed for certain health conditions, following an assessment of its safety, effectiveness, and quality. For example, in November 2022, the US-based Food and Drug Administration issued an Emergency Use Authorization (EUA) for Kineret (anakinra) to treat adults in hospital with pneumonia related to COVID-19 who needed additional oxygen. The objective was to minimize the chances of acute respiratory failure. The clearance was granted based on the outcomes of the SAVE-MORE phase 3 trial, which demonstrated that starting treatment early with Kineret enhanced patient results. Kineret functions by inhibiting cytokines IL-1a and IL-1ß, both of which contribute to the extreme inflammatory response seen in severe COVID-19 patients. Even though it doesn’t have full FDA authorization for this use, it’s permitted for temporary use throughout the public health crisis.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21095

Which geographic areas are influencing the growth of the anakinra market?

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Chemotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Hormone Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Gastrointestinal Bleeding Treatment Devices Size Global Market Report 2025

https://thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: